Acute Toxicity of pCK-VEGF in Rata and Mice

Vasular Endothelial Growth Factor 165 (VEGF165) 발현 벡터 (pCK-VEGF)의 랫드와 마우스에서의 급성독성

  • 김선영 (서울대학교 유전공학연구소) ;
  • 이영주 (서울대학교 유전공학연구소, (주)바이로메드) ;
  • 조홍찬 (서울대학교 유전공학과) ;
  • 박은진 ((주) 바이로메드) ;
  • 안병옥 (동아제약(주)연구소) ;
  • 김덕경 (성균관대학교 의과대학, 삼성서울병원 순환기내과)
  • Published : 2000.03.01

Abstract

It has been demonstrated that the injection of naked DNA expressing vascular endothelial growth factor 165(VEGFl165) to the affected area can provide significant therapeutic effects on peripherol artery occlusive diseases. Success with this type of gene therapy highly depends on the quality of the vector delivering the therapeutic gene, especially in terms of the level and duration of gene expression in the localized area. We have recently developed a vector expressing VEGF165(pCK-VEGF) for the treatment of peripheral artery occulsive diseases and demonstrated high level expression of VEGF165 in mouse skeletal muscle. This study was designed to assess the acute toxicity of intramuscularly injected pCK-VEGF in BALB/c mice and Sprague-Dawely rats. There was no evidence of any changes in clinical signs, body weights, or gross pathological signs. We estimate LD50 values of pCK-VEGF higher than 50mg/kg in mice and 20 mg/kg in rats by intramuscular injection.

Keywords

References

  1. Ctrculation v.97 Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia Baumgartner, I.;Pieczek, A.;Manor, O.;Blair, R.;Kearney, M.;Walsh, K.;Isner, J.M.
  2. J. Appl. Physiol. v.77 No lung toxicity after repeated aerosol or intravenous delivery of plasmid-cationic liposome complexes Canonico, A.E.;Plitman, J.D.;Conary, J.T.;Meyrick, B.O.;Brigham, K.
  3. Minutes of Meeting Recombinant DNA Advisory Committee Department of Health and Human Services, National Institutes of Health
  4. Endocrine Reviews v.13 Molecular and Biological properties of the vascular endothelial growth factor family of proteins Ferra, N.;Houck, K.;Jakeman, L.;Leung, D.
  5. Hum. Gene Ther. v.7 Arterial gene transfer for therapeutic angiogenesis in patients with peripheral artery disease Isner, J. M.;Walsh, K.;Symes, J.;Picezek, A.;Takeshita, S.;Lowry, J.;Rosenfield, K.;Weir, L.;Brogi, E.;Juragi, D.
  6. Hum. Gene Ther. v.3 Gene transfer in vivo with DNA-liposome complexes: lack of autoimmunity and gonadal localization Nabel, E.G.;Gordon, D.;Yang, Z.Y.;Xu, L.;San, H.;Plautz, G.E.;Wu, B.Y.;Gao, X.;Huang, L.;Nabel, G.J.
  7. Ann. N.Y. Acad. Sci. v.772 Potential DNA vaccine integration into host cell genome Nichols, W. W.;Ledwith, B. J.;Manam, S.V.;Troilo, P.J.
  8. Hum. Gene Ther. v.6 Cancer gene therapy using plasmid DNA: Safety evaluation in rodents and non-human primates Parker, S.E.;Vahlsing, H.L.;Serfilippi, L.M.;Franklin, C.L.;Doh, S.G.;Gromkowski, S.H.;Lew, D.;Manthorpe, C.M.;Norman, J.
  9. Hum. Gene Ther. v.10 Plasmid DNA Malaria Vaccine: Tissue Distribution and safety studies in mice and rabbits Parker, S.E.;Borellini, F.;Wenk, M.L.;Hobart, P.;Hoffman, S.L.;Hedstrom, R.;Lee, T.;Norman, J.A.
  10. Hum. Gene Ther. v.4 Safety and short-term toxicity of a novel cationic lipid formulation for human gene therapy San, H.;Yang, Z.Y.;Pompili, V.J.;Jaffe, M.L.;Plautz, G.E.;Felgner, J.H.;Wheeler, C.J.;Felgner, P.L.;Gao, X.;Huang, L.;Gordon, D.;Nabel, G.J.;Nabel, E.G.
  11. Hum. Gene Ther. v.3 Gene transfer in vivo with DNA-liposome complexes: Safety and acute toxicity in mice Stewart, M.J.;Plautz, G.E.;Del Buono, L.;Yang, Y.;Xu, L.;Gao, X.;Huang, L.;Nabel, E.G.;Nabel, J.
  12. J. Biol. Chem. v.266 The human gene for vascular endothelial growth factor multiple protein forms are encoded through alternative exon splicing Tischer, E.;Mitchell, R.;Hartaman, T.;Silva, M.;Gospodarowics, D.;Fiddes, J.;Abraham, J.
  13. 대한 민국 특허 출원 제98-63711호 이종유전자유래의 유전자 발현 조절요소를 포함하는 강력한 전사활성을 가진 진핵 세포발현 벡터 이영주;유승신;김종묵;나영순;고규영;김덕경;김선영
  14. J. Toxicol. Pub. Health v.15 Naked DNA를 이용한 말초동맥폐색질환 치료용 VEGF 발현벡터의 안전성 실험 이영주;박은진;조흥찬;서연림;김덕경;김선영